Hoth Therapeutics (HOTH) “announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics Completes Registered Direct Offering Financing
- Hoth Therapeutics announces $2M registered direct offering
- Hoth Therapeutics reports results from ongoing HT-001 program
- Hoth Therapeutics announces issuance of Chinese patent
- Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity